Revvity, Inc. logo RVTY - Revvity, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 15
HOLD 14
SELL 0
STRONG
SELL 0
| PRICE TARGET: $111.57 DETAILS
HIGH: $125.00
LOW: $95.00
MEDIAN: $115.00
CONSENSUS: $111.57
UPSIDE: 1.00%

Stock News

Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs

Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the development of the T-SPOT™ A201, a next-generation high-throughput automated platform designed to support the performance advantages of T-SPOT.TB™ testing for large-volume clinical labs, enabling a reliable, accurate solution for latent tuberculosis (TB) detection. Tuberculosis remains a critical global health challenge, with testing demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies.

Jul 23, 2026 04:00 AM • businesswire.com
Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One

Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. announced that its Revvity Signals Software business is launching Signals for Startups, a new program designed to help emerging biotechnology companies adopt scalable informatics capabilities earlier in their growth journey. Built for early-stage biotechs, the program combines access to enterprise-grade Signals software with guided onboarding and best-practice configurations tailored specifically for smaller biotechs to help accelerate innovation,.

Jul 20, 2026 04:00 AM • businesswire.com
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure

Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today published its 2026 Impact Report, highlighting the Company's sustainability, social and governance strategy, initiatives and performance. The annual report showcases how the Company continues to translate innovation into real-world impact, while embedding responsible and sustainable practices through its operations. "At Revvity, we believe scientific innovation and responsible business practices go hand in hand," said Prahlad Sin.

Jul 20, 2026 04:00 AM • businesswire.com
Revvity to Hold Earnings Call on Tuesday, August 4, 2026

Revvity to Hold Earnings Call on Tuesday, August 4, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2026 financial results prior to market open on Tuesday, August 4, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of.

Jul 08, 2026 04:00 AM • businesswire.com
Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration

Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol (MCP) connectors, enabling scientists to access Signals AI capabilities and connected R&D knowledge through Claude, including Claude Science, Anthropic's new AI workbench for scientific research. As organizations increasingly adopt artificial intelligence to accelerate scientific research, the challenge is ensuring AI mo.

Jul 01, 2026 04:00 AM • businesswire.com
Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D

Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One™ platform, new capabilities from Signals AI help scientists transform connected R&D data into understanding, decisions and action using natural language within their existing workflows. As scientific organizations generate increasing volumes of data acr.

Jun 22, 2026 04:00 AM • businesswire.com
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This offering complements the Company's FDA-cleared ChLIA tests for free testosterone and sex hormone-binding globulin (SHBG), delivering a first of its kind, complete solution for testosterone-related disorders on a single pla.

May 13, 2026 04:00 AM • businesswire.com
Revvity Announces Financial Results for the First Quarter of 2026

Revvity Announces Financial Results for the First Quarter of 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the quarter was $711 million, as compared to $665 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $76 million, as compared to $72 million for the same perio.

May 05, 2026 02:00 AM • businesswire.com

Price Targets